L-DOPA/DDCI

( DrugBank: L-DOPA / KEGG DRUG: Levodopa )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	9

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 9 of 9 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04990284 (ClinicalTrials.gov)	November 29, 2021	27/7/2021	eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study ...	Parkinson Disease	Drug: Opicapone;Drug: L-DOPA/DDCI	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	100	Phase 4	Germany;Italy;Portugal;Spain;United Kingdom
2	EUCTR2020-005011-52-PT (EUCTR)	03/09/2021	29/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Portugal;Serbia;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
3	EUCTR2020-005011-52-BE (EUCTR)	19/07/2021	07/04/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Trade Name: Ongentys Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
4	EUCTR2020-005011-52-FR (EUCTR)	23/06/2021	01/04/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Trade Name: Ongentys Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
5	NCT04978597 (ClinicalTrials.gov)	May 31, 2021	5/7/2021	Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel-Group Study to Evaluate the E ...	Parkinson	Drug: Opicapone 50 mg;Drug: Placebo	Bial - Portela C S.A.	NULL	Recruiting	30 Years	80 Years	All	324	Phase 3	Bulgaria
6	EUCTR2020-005011-52-IT (EUCTR)	28/05/2021	04/06/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Trade Name: Ongentys Product Name: Opicapone Product Code: [BIA 9-1067] INN or Proposed INN: OPICAPONE	BIAL-Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
7	EUCTR2020-005011-52-BG (EUCTR)	17/05/2021	22/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
8	EUCTR2020-005011-52-CZ (EUCTR)	12/05/2021	04/03/2021	Efficacy and Safety of Opicapone, as an Add-on to Stable L-DOPA Plus DDCI Therapy, in Early Idiopath ...	A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the E ...	Early Idiopathic Parkinson’s disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Ter ...	Product Name: Opicapone Product Code: BIA 9-1067 INN or Proposed INN: OPICAPONE	BIAL – Portela & Cª, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	324	Phase 3	Serbia;Portugal;Czechia;Spain;Ukraine;Turkey;Italy;United Kingdom;France;Czech Republic;Belgium;Pola ...
9	EUCTR2010-021860-13-CZ (EUCTR)	24/06/2011	09/11/2010	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENO ...	EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH WEARING-OFF” PHENO ...	Adjunct to levodopa L-DOPA/DDCIfor use in patients with Parkinson’s disease (PD) and end-of-dose mot ...	Product Name: BIA 9-1067 Product Code: BIA 9-1067 INN or Proposed INN: BIA 9-1067 Other descriptive nam ...	BIAL - Portela & Ca, S.A.	NULL	Not Recruiting			Female: yes Male: yes	550		Serbia;Portugal;Slovakia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Montenegro;Italy;France; ...

First Previous1Next Last